M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
received:
26
06
2020
accepted:
13
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
5
2
2021
Statut:
epublish
Résumé
Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined "M1" macrophage and "M1"/"M2" ratio by transcriptomic signatures using xCell. We investigated the association between high level of "M1" macrophage or "M1"/"M2" ratio and the tumor immune microenvironment by analyzing the transcriptome of publicly available cohorts, TCGA and METABRIC. We found that "M1" high tumors were not associated with prolonged survival compared with "M1" low tumors, or with the response to neoadjuvant chemotherapy. "M1" high tumors were associated with clinically aggressive features and "M1" high tumors enriched the cell proliferation and cell cycle related gene sets in GSEA. At the same time, "M1" high tumors were associated with high immune activity and favorable tumor immune microenvironment, as well as high expression of immune check point molecules. Strikingly, all these results were mirrored in "M1"/"M2" ratio high tumors. In conclusion, transcriptomically defined "M1" or "M1"/"M2" high tumors were associated with aggressive cancer biology and favorable tumor immune microenvironment but not with survival benefit, which resembled only part of their conventional clinical characteristics.
Identifiants
pubmed: 33024179
doi: 10.1038/s41598-020-73624-w
pii: 10.1038/s41598-020-73624-w
pmc: PMC7538579
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
16554Subventions
Organisme : NIH HHS
ID : R01CA160688
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016056
Pays : United States
Références
DeNardo, D. G. & Coussens, L. M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9, 212–212. https://doi.org/10.1186/bcr1746 (2007).
doi: 10.1186/bcr1746
pubmed: 17705880
pmcid: 2206719
Deng, L. et al. Immune profiles of tumor microenvironment and clinical prognosis among women with triple-negative breast cancer. Cancer Epidemiol. Biomark. Prev. https://doi.org/10.1158/1055-9965.Epi-19-0469 (2019).
doi: 10.1158/1055-9965.Epi-19-0469
Guerriero, J. L. Macrophages: the road less traveled, changing anticancer therapy. Trends Mol. Med. 24, 472–489. https://doi.org/10.1016/j.molmed.2018.03.006 (2018).
doi: 10.1016/j.molmed.2018.03.006
pubmed: 29655673
pmcid: 5927840
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867. https://doi.org/10.1038/nature01322 (2002).
doi: 10.1038/nature01322
pubmed: 12490959
pmcid: 2803035
Biswas, S. K., Allavena, P. & Mantovani, A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35, 585–600. https://doi.org/10.1007/s00281-013-0367-7 (2013).
doi: 10.1007/s00281-013-0367-7
pubmed: 23657835
Parisi, L. et al. Macrophage polarization in chronic inflammatory diseases: Killers or builders?. J. Immunol. Res. 2018, 8917804. https://doi.org/10.1155/2018/8917804 (2018).
doi: 10.1155/2018/8917804
pubmed: 29507865
pmcid: 5821995
De Vito, A. et al. Overexpression of murine Rnaset2 in a colon syngeneic mouse carcinoma model leads to rebalance of intra-tumor M1/M2 macrophage ratio, activation of T cells, delayed tumor growth, and rejection. Cancers https://doi.org/10.3390/cancers12030717 (2020).
doi: 10.3390/cancers12030717
pubmed: 32545553
pmcid: 7352325
Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J Clin Investig 122, 787–795. https://doi.org/10.1172/jci59643 (2012).
doi: 10.1172/jci59643
pubmed: 22378047
Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20. https://doi.org/10.1016/j.immuni.2014.06.008 (2014).
doi: 10.1016/j.immuni.2014.06.008
pubmed: 25035950
pmcid: 25035950
Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27, 451–483. https://doi.org/10.1146/annurev.immunol.021908.132532 (2009).
doi: 10.1146/annurev.immunol.021908.132532
pubmed: 19105661
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (Baltimore, Md.: 1950) 164, 6166–6173. https://doi.org/10.4049/jimmunol.164.12.6166 (2000).
doi: 10.4049/jimmunol.164.12.6166
Honkanen, T. J. et al. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Sci. Rep. 9, 10961–10961. https://doi.org/10.1038/s41598-019-47375-2 (2019).
doi: 10.1038/s41598-019-47375-2
pubmed: 31358801
pmcid: 6662906
Medrek, C., Ponten, F., Jirstrom, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306. https://doi.org/10.1186/1471-2407-12-306 (2012).
doi: 10.1186/1471-2407-12-306
pubmed: 22824040
pmcid: 3414782
Schnellhardt, S. et al. Accelerated partial breast irradiation: macrophage polarisation shift classification identifies high-risk tumours in early hormone receptor-positive breast cancer. Cancers 12, E446. https://doi.org/10.3390/cancers12020446 (2020).
doi: 10.3390/cancers12020446
pubmed: 32075091
Jeong, H., Hwang, I., Kang, S. H., Shin, H. C. & Kwon, S. Y. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J. Breast Cancer 22, 38–51. https://doi.org/10.4048/jbc.2019.22.e5 (2019).
doi: 10.4048/jbc.2019.22.e5
pubmed: 30941232
pmcid: 6438840
Ma, J. et al. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10, 112. https://doi.org/10.1186/1471-2407-10-112 (2010).
doi: 10.1186/1471-2407-10-112
pubmed: 20338029
pmcid: 2851690
Yuan, R. et al. Reversing the polarization of tumor-associated macrophages inhibits tumor metastasis. Int. Immunopharmacol. 49, 30–37. https://doi.org/10.1016/j.intimp.2017.05.014 (2017).
doi: 10.1016/j.intimp.2017.05.014
pubmed: 28550732
Scaldaferri, D. et al. The human RNASET2 protein affects the polarization pattern of human macrophages in vitro. Immunol. Lett. 203, 102–111. https://doi.org/10.1016/j.imlet.2018.09.005 (2018).
doi: 10.1016/j.imlet.2018.09.005
pubmed: 30218741
Oshi, M. et al. G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-positive breast cancer. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21082921 (2020).
doi: 10.3390/ijms21082921
pubmed: 32971948
pmcid: 7370149
Tokumaru, Y. et al. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. Am. J. Cancer Res. 10, 897–907 (2020).
pubmed: 32266098
pmcid: 7136911
Asaoka, M., Patnaik, S. K., Zhang, F., Ishikawa, T. & Takabe, K. Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response. Breast Cancer Res. Treat. https://doi.org/10.1007/s10549-020-05630-5 (2020).
doi: 10.1007/s10549-020-05630-5
pubmed: 32285241
Takahashi, H. et al. Biologically aggressive phenotype and anti-cancer immunity counterbalance in breast cancer with high mutation rate. Sci. Rep. 10, 1852–1852. https://doi.org/10.1038/s41598-020-58995-4 (2020).
doi: 10.1038/s41598-020-58995-4
pubmed: 32024876
pmcid: 7002588
Takeshita, T., Yan, L., Asaoka, M., Rashid, O. & Takabe, K. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor. Sci. Rep. 9, 16942. https://doi.org/10.1038/s41598-019-53482-x (2019).
doi: 10.1038/s41598-019-53482-x
pubmed: 31729458
pmcid: 6858361
Asaoka, M., Ishikawa, T., Takabe, K. & Patnaik, S. K. APOBEC3-mediated RNA editing in breast cancer is associated with heightened immune activity and improved survival. Int. J. Mol. Sci. 20, 5621. https://doi.org/10.3390/ijms20225621 (2019).
doi: 10.3390/ijms20225621
pmcid: 6888598
Narayanan, S. et al. Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer. Sci. Rep. 9, 13455–13455. https://doi.org/10.1038/s41598-019-49878-4 (2019).
doi: 10.1038/s41598-019-49878-4
pubmed: 31530839
pmcid: 6748965
Okano, M. et al. Triple-negative breast cancer with high levels of annexin A1 expression is associated with mast cell infiltration, inflammation, and angiogenesis. Int. J. Mol. Sci. 20, 4197. https://doi.org/10.3390/ijms20174197 (2019).
doi: 10.3390/ijms20174197
pmcid: 6747082
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220–220. https://doi.org/10.1186/s13059-017-1349-1 (2017).
doi: 10.1186/s13059-017-1349-1
pubmed: 5688663
pmcid: 5688663
Katsuta, E. et al. High MYC mRNA expression is more clinically relevant than MYC DNA amplification in triple-negative breast cancer. Int. J. Mol. Sci. 21, E217. https://doi.org/10.3390/ijms21010217 (2019).
doi: 10.3390/ijms21010217
pubmed: 31905596
Okano, M. et al. Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival. Int. J. Mol. Sci. 20, 2655. https://doi.org/10.3390/ijms20112655 (2019).
doi: 10.3390/ijms20112655
pmcid: 6600230
Oshi, M. et al. A novel 4-gene score to predict survival, distant metastasis and response to neoadjuvant therapy in breast cancer. Cancers https://doi.org/10.3390/cancers12051148 (2020).
doi: 10.3390/cancers12051148
pubmed: 32370309
pmcid: 7281399
Tokumaru, Y. et al. High expression of microRNA-143 is Associated with favorable tumor immune microenvironment and better survival in estrogen receptor positive breast cancer. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21093213 (2020).
doi: 10.3390/ijms21093213
pubmed: 32971948
pmcid: 7246786
Tokumaru, Y. et al. High expression of miR-34a associated with less aggressive cancer biology but not with survival in breast cancer. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21093045 (2020).
doi: 10.3390/ijms21093045
pubmed: 32971948
pmcid: 7246786
Glück, S. et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res. Treat. 132, 781–791. https://doi.org/10.1007/s10549-011-1412-7 (2012).
doi: 10.1007/s10549-011-1412-7
pubmed: 21373875
Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305, 1873–1881. https://doi.org/10.1001/jama.2011.593 (2011).
doi: 10.1001/jama.2011.593
pubmed: 21558518
pmcid: 5638042
Miyake, T. et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 103, 913–920. https://doi.org/10.1111/j.1349-7006.2012.02231.x (2012).
doi: 10.1111/j.1349-7006.2012.02231.x
pubmed: 22320227
Popovici, V. et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 12, R5. https://doi.org/10.1186/bcr2468 (2010).
doi: 10.1186/bcr2468
pubmed: 20064235
pmcid: 2880423
Sporn, J. C., Katsuta, E., Yan, L. & Takabe, K. Expression of MicroRNA-9 is associated with overall survival in breast cancer patients. J. Surg. Res. 233, 426–435. https://doi.org/10.1016/j.jss.2018.08.020 (2019).
doi: 10.1016/j.jss.2018.08.020
pubmed: 30502282
Takeshita, T. et al. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer. Am. J. Transl. Res. 11, 6507–6521 (2019).
pubmed: 31737202
pmcid: 6834504
Terakawa, T. et al. High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget 9, 14207–14218. https://doi.org/10.18632/oncotarget.24453 (2018).
doi: 10.18632/oncotarget.24453
pubmed: 29581838
pmcid: 5865664
Young, J. et al. Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival. Oncotarget 8, 99978–99989. https://doi.org/10.18632/oncotarget.21577 (2017).
doi: 10.18632/oncotarget.21577
pubmed: 29245954
pmcid: 5725145
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812-830.e814. https://doi.org/10.1016/j.immuni.2018.03.023 (2018).
doi: 10.1016/j.immuni.2018.03.023
pubmed: 5982584
pmcid: 5982584
Narayanan, S. et al. Cytolytic activity score to assess anticancer immunity in colorectal cancer. Ann. Surg. Oncol. 25, 2323–2331. https://doi.org/10.1245/s10434-018-6506-6 (2018).
doi: 10.1245/s10434-018-6506-6
pubmed: 29770915
pmcid: 6237091
Takahashi, H. et al. Immune cytolytic activity for comprehensive understanding of immune landscape in hepatocellular carcinoma. Cancers 12, 1. https://doi.org/10.3390/cancers12051221 (2020).
doi: 10.3390/cancers12051221
Akinrinmade, O. A. et al. CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases. Biomedicines https://doi.org/10.3390/biomedicines5030056 (2017).
doi: 10.3390/biomedicines5030056
pubmed: 28895912
pmcid: 5618314
Roussel, M. et al. Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. J. Leukoc. Biol. 102, 437–447. https://doi.org/10.1189/jlb.5MA1116-457R (2017).
doi: 10.1189/jlb.5MA1116-457R
pubmed: 28400539
pmcid: 6608074
Lu, J. & Ma, L. The role of tumor-associated macrophages in the development, metastasis and treatment of breast cancer. Pathol. Res. Pract. 216, 153085. https://doi.org/10.1016/j.prp.2020.153085 (2020).
doi: 10.1016/j.prp.2020.153085
pubmed: 32825953
Qiu, S. Q. et al. Tumor-associated macrophages in breast cancer: Innocent bystander or important player?. Cancer Treat. Rev. 70, 178–189. https://doi.org/10.1016/j.ctrv.2018.08.010 (2018).
doi: 10.1016/j.ctrv.2018.08.010
pubmed: 30227299
von der Lippe Gythfeldt, H. et al. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer. Int. J. Cancer https://doi.org/10.1002/ijc.33108 (2020).
doi: 10.1002/ijc.33108
pubmed: 32488909
Campbell, M. J. et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat. 128, 703–711. https://doi.org/10.1007/s10549-010-1154-y (2011).
doi: 10.1007/s10549-010-1154-y
pubmed: 20842526
Wang, S. et al. Metabolic reprogramming of macrophages during infections and cancer. Cancer Lett. 452, 14–22. https://doi.org/10.1016/j.canlet.2019.03.015 (2019).
doi: 10.1016/j.canlet.2019.03.015
pubmed: 30905817
Mantovani, A. & Allavena, P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435–445. https://doi.org/10.1084/jem.20150295 (2015).
doi: 10.1084/jem.20150295
pubmed: 25753580
pmcid: 4387285
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416. https://doi.org/10.1038/nrclinonc.2016.217 (2017).
doi: 10.1038/nrclinonc.2016.217
pubmed: 28117416
pmcid: 5480600
Leek, R. D. et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625–4629 (1996).
pubmed: 8840975
Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61. https://doi.org/10.1016/j.immuni.2014.06.010 (2014).
doi: 10.1016/j.immuni.2014.06.010
pubmed: 25035953
pmcid: 4137410
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121. https://doi.org/10.1056/NEJMoa1809615 (2018).
doi: 10.1056/NEJMoa1809615
pubmed: 30345906
Tokumaru, Y., Joyce, D. & Takabe, K. Current status and limitations of immunotherapy for breast cancer. Surgery S0039–6060(0019), 30674–30679. https://doi.org/10.1016/j.surg.2019.09.018 (2019).
doi: 10.1016/j.surg.2019.09.018